ARTICLES BY ERIN HARRIS

• Tessera Therapeutics Advances In Vivo Gene Therapy For SCD

  2/24/2025

  Tessera Therapeutics' CSO, Michael Holmes, Ph.D., shares information on the company's Gene Writers for sickle cell disease (SCD) and how their work has garnered investment from of the Bill & Melinda Gates Foundation to support their efforts.

• Excision BioTherapeutics & Guide RNA

  7/27/2023

  Excision’s CEO Daniel Dornbusch to dig into its CRISPR-based therapy, EBT-101, as well as Guide RNA (gRNA) and why it is critical to EBT-101’s success. 

• DTx Pharma And The Near-Term Future Of RNA Therapeutics

  11/21/2022

  To learn more about the near-term future of RNA therapeutics, the advantages of short interfering RNA (siRNA) over other RNA therapeutics and more, I caught up with DTx Pharma's CEO Arthur Suckow.

• The Promising Future Of Oligonucleotides

  10/31/2022

  Episode 35 of Cell & Gene: The Podcast features Dr. Michelle Mellion, PepGen’s SVP Head of Clinical Development at Cambridge, MA-based biotech PepGen. In it, Dr. Mellion talks all about the company’s oligonucleotide therapeutics that were developed to treat severe neuromuscular and neurologic diseases, such as Duchenne Muscular Dystrophy (DMD).

• Breakdown Of Cell & Gene Live: Advancements In Targeted mRNA Delivery

  9/21/2022

  During our Cell & Gene Live, Advancements in Targeted mRNA Delivery, Dr. Murat Kalayoglu, CEO of Cartesian Therapeutics, Walter Strapps, Ph.D., Co-Founder and CEO of Carver Biosciences, and I spent the hour talking about the delivery of mRNA-based therapeutics. Our expert panelists discussed the specific challenges and opportunities in delivering conventional RNA therapeutics clinically, as well as the specific challenges and opportunities in delivering the RNA cell therapies clinically. You can view the full-length presentation here. For your convenience, we’ve broken down the hour into bite-size chunks based on the important topics we discussed throughout the hour.

• Capstan Therapeutics' Next Steps For In Vivo CAR Therapies

  9/19/2022

  Capstan Therapeutics is a brand-new biotech company dedicated to developing and delivering precise in vivo cell engineering to patients. With $165 million in financing, Capstan Therapeutics aims to build on the foundational insights of leaders in mRNA and cell therapy from the University of Pennsylvania. Laura Shawver, Ph.D., leads the company as President and CEO, and on the heels of the biotech’s recent news, I caught up with her to learn more about the company’s plans for developing in vivo CAR therapies.

• RNA's Delivery Challenges

  3/16/2022

  Targeted delivery is a major hurdle for effective RNA Therapeutics, a hurdle that must be overcome to broaden the application of clinical translation of cell therapeutics. The mRNA-based therapeutic modality is new to emerging field of immuno-oncology, often referred to as immunotherapy.